Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2020

Open Access 01-12-2020 | Hyperthyroidism | Case report

Unusual onset of thyroid associated orbitopathy during pregnancy: case report and review of literature

Authors: Janos K. Aranyosi, Tamas Deli, Annamaria Erdei, Geza Toth, Attila Jakab, Mariann Fodor, Endre V. Nagy, Bernadett Ujhelyi

Published in: BMC Endocrine Disorders | Issue 1/2020

Login to get access

Abstract

Background

Thyroid associated orbitopathy (TAO) is the most common extrathyroidal complication of Graves’ disease. The disease course ranges from mild, where symptomatic therapy is sufficient, to severe, where high dose steroid administration or orbital decompression surgery is required. Women of their reproductive age are more likely to be affected. Although pregnancy is a state of enhanced immune tolerance, TAO may develop or worsen in 0.2–0.4% of pregnant women.

Case presentation

We present the case of a 19-year-old woman who has developed hyperthyroidism and progressive TAO during the second trimester of her third pregnancy, which has improved postpartum. The possible mechanisms and the importance of follow up in pregnancy is discussed.

Conclusions

Expectant mothers with Graves’ disease require follow up of eye signs throughout pregnancy, preferably in the setting of a thyroid-eye clinic.
Literature
1.
go back to reference Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977;7(6):481–93.CrossRef Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977;7(6):481–93.CrossRef
2.
go back to reference Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK, et al. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. None. 2006;91(12):4873–80. Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK, et al. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. None. 2006;91(12):4873–80.
3.
go back to reference Balucan FS, Morshed SA, Davies TF. Thyroid autoantibodies in pregnancy: their role, regulation and clinical relevance. J Thyroid Res. 2013;2013:182472.CrossRef Balucan FS, Morshed SA, Davies TF. Thyroid autoantibodies in pregnancy: their role, regulation and clinical relevance. J Thyroid Res. 2013;2013:182472.CrossRef
4.
go back to reference Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1(3):238–49.CrossRef Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1(3):238–49.CrossRef
5.
go back to reference Chin YH, Ng CH, Lee MH, Koh JWH, Kiew J, Yang SP, et al. Prevalence of thyroid eye disease in graves’ disease: a meta-analysis and systematic review. Clin Endocrinol. 2020;93(4):363–74.CrossRef Chin YH, Ng CH, Lee MH, Koh JWH, Kiew J, Yang SP, et al. Prevalence of thyroid eye disease in graves’ disease: a meta-analysis and systematic review. Clin Endocrinol. 2020;93(4):363–74.CrossRef
6.
go back to reference Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993;14(6):747–93.PubMed Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993;14(6):747–93.PubMed
7.
go back to reference Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the Management of Graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167–86.CrossRef Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the Management of Graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167–86.CrossRef
8.
go back to reference Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves Ophthalmopathy. Med Clin N Am. 2012;96(2):311–28.CrossRef Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves Ophthalmopathy. Med Clin N Am. 2012;96(2):311–28.CrossRef
9.
go back to reference Buyon JP. The effects of pregnancy on autoimmune diseases. J Leukoc Biol. 1998;63(3):281-7.CrossRef Buyon JP. The effects of pregnancy on autoimmune diseases. J Leukoc Biol. 1998;63(3):281-7.CrossRef
10.
go back to reference Adams Waldorf KM, Nelson JL. Autoimmune disease during pregnancy and the pregnancy microchimerism legacy of pregnancy. Immunol Investig. 2008;37(5):631–44.CrossRef Adams Waldorf KM, Nelson JL. Autoimmune disease during pregnancy and the pregnancy microchimerism legacy of pregnancy. Immunol Investig. 2008;37(5):631–44.CrossRef
11.
go back to reference Baer AN, Witter FR, Petri M. Lupus and pregnancy. Obstet Gynecol Surv. 2011;66(10):639–53.CrossRef Baer AN, Witter FR, Petri M. Lupus and pregnancy. Obstet Gynecol Surv. 2011;66(10):639–53.CrossRef
12.
go back to reference Gaberšček S, Zaletel K. Thyroid physiology and autoimmunity in pregnancy and after delivery. Expert Rev Clin Immunol. 2011;7(5):697–707.CrossRef Gaberšček S, Zaletel K. Thyroid physiology and autoimmunity in pregnancy and after delivery. Expert Rev Clin Immunol. 2011;7(5):697–707.CrossRef
13.
go back to reference Chan GW, Mandel SJ. Therapy insight: management of graves’ disease during pregnancy. Nat Rev Endocrinol. 2007;3(6):470–8.CrossRef Chan GW, Mandel SJ. Therapy insight: management of graves’ disease during pregnancy. Nat Rev Endocrinol. 2007;3(6):470–8.CrossRef
14.
go back to reference Amino N, Izumi Y, Hidaka Y, Takeoka K, Nakata Y, Tatsumi K-I, et al. No increase of blocking type anti-thyrotropin receptor antibodies during pregnancy in patients with Graves’ disease. J Clin Endocrinol Metab. 2003;88(12):5871–4.CrossRef Amino N, Izumi Y, Hidaka Y, Takeoka K, Nakata Y, Tatsumi K-I, et al. No increase of blocking type anti-thyrotropin receptor antibodies during pregnancy in patients with Graves’ disease. J Clin Endocrinol Metab. 2003;88(12):5871–4.CrossRef
15.
go back to reference Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. Guidelines of the American Thyroid Association for the diagnosis and Management of Thyroid Disease during Pregnancy and the postpartum. Thyroid. 2017;27(3):315–89.CrossRef Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. Guidelines of the American Thyroid Association for the diagnosis and Management of Thyroid Disease during Pregnancy and the postpartum. Thyroid. 2017;27(3):315–89.CrossRef
16.
go back to reference Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, et al. Clinical assessment of patients with graves’ orbitopathy: the European group on graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155(3):387–9.CrossRef Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, et al. Clinical assessment of patients with graves’ orbitopathy: the European group on graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155(3):387–9.CrossRef
17.
go back to reference Rapoport B, McLachlan SM. The thyrotropin receptor in graves’ disease. Thyroid. 2007;17(10):911–22.CrossRef Rapoport B, McLachlan SM. The thyrotropin receptor in graves’ disease. Thyroid. 2007;17(10):911–22.CrossRef
18.
19.
go back to reference Stafford IP, Dildy GA, Miller JM. Severe graves’ ophthalmopathy in pregnancy. Obstet Gynecol. 2005;105(5 Pt 2):1221–3.CrossRef Stafford IP, Dildy GA, Miller JM. Severe graves’ ophthalmopathy in pregnancy. Obstet Gynecol. 2005;105(5 Pt 2):1221–3.CrossRef
20.
go back to reference Branch DW. Physiologic adaptations of pregnancy. Am J Reprod Immunol. 1992;28(3–4):120–2.CrossRef Branch DW. Physiologic adaptations of pregnancy. Am J Reprod Immunol. 1992;28(3–4):120–2.CrossRef
21.
go back to reference Gregory CD, Shah LP, Lee H, Scott IV, Golding PR. Cytotoxic reactivity of human natural killer (NK) cells during normal pregnancy: a longitudinal study. J Clin Lab Immunol. 1985;18(4):175–81.PubMed Gregory CD, Shah LP, Lee H, Scott IV, Golding PR. Cytotoxic reactivity of human natural killer (NK) cells during normal pregnancy: a longitudinal study. J Clin Lab Immunol. 1985;18(4):175–81.PubMed
22.
go back to reference Maroulis GB, Buckley RH, Younger JB. Serum immunoglobulin concentrations during normal pregnancy. American Journal of Obstetrics & Gynecology. 1971;109(7):971–6.CrossRef Maroulis GB, Buckley RH, Younger JB. Serum immunoglobulin concentrations during normal pregnancy. American Journal of Obstetrics & Gynecology. 1971;109(7):971–6.CrossRef
23.
go back to reference Sridama V, Pacini F, Yang SL, Moawad A, Reilly M, DeGroot LJ. Decreased levels of helper T cells: a possible cause of immunodeficiency in pregnancy. N Engl J Med. 1982;307(6):352–6.CrossRef Sridama V, Pacini F, Yang SL, Moawad A, Reilly M, DeGroot LJ. Decreased levels of helper T cells: a possible cause of immunodeficiency in pregnancy. N Engl J Med. 1982;307(6):352–6.CrossRef
24.
go back to reference Saito S, Nakashima A, Shima T, Ito M. Review article: Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010;63(6):601–10.CrossRef Saito S, Nakashima A, Shima T, Ito M. Review article: Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010;63(6):601–10.CrossRef
25.
go back to reference Guerin LR, Prins JR, Robertson SA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum Reprod Update. 2009;15(5):517–35.CrossRef Guerin LR, Prins JR, Robertson SA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum Reprod Update. 2009;15(5):517–35.CrossRef
26.
go back to reference Mjösberg J, Berg G, Ernerudh J, Ekerfelt C. CD4+ CD25+ regulatory T cells in human pregnancy: development of a Treg-MLC-ELISPOT suppression assay and indications of paternal specific Tregs. Immunology. 2007;120(4):456–66.CrossRef Mjösberg J, Berg G, Ernerudh J, Ekerfelt C. CD4+ CD25+ regulatory T cells in human pregnancy: development of a Treg-MLC-ELISPOT suppression assay and indications of paternal specific Tregs. Immunology. 2007;120(4):456–66.CrossRef
27.
go back to reference Weetman AP. Immunity, thyroid function and pregnancy: molecular mechanisms. Nat Rev Endocrinol. 2010 Jun;6(6):311–8.CrossRef Weetman AP. Immunity, thyroid function and pregnancy: molecular mechanisms. Nat Rev Endocrinol. 2010 Jun;6(6):311–8.CrossRef
28.
go back to reference Galofre JC, Davies TF. Autoimmune thyroid disease in pregnancy: a review. J Women's Health (Larchmt). 2009;18(11):1847–56.CrossRef Galofre JC, Davies TF. Autoimmune thyroid disease in pregnancy: a review. J Women's Health (Larchmt). 2009;18(11):1847–56.CrossRef
30.
go back to reference Mestman JH, Goodwin TM, Montoro MM. Thyroid disorders of pregnancy. Endocrinol Metab Clin N Am. 1995;24(1):41–71.CrossRef Mestman JH, Goodwin TM, Montoro MM. Thyroid disorders of pregnancy. Endocrinol Metab Clin N Am. 1995;24(1):41–71.CrossRef
31.
go back to reference Abbouda A, Trimboli P, Bruscolini A. A Mild Grave’s Ophthalmopathy During Pregnancy. Seminars Ophthalmol. 2014;29(1):8–10.CrossRef Abbouda A, Trimboli P, Bruscolini A. A Mild Grave’s Ophthalmopathy During Pregnancy. Seminars Ophthalmol. 2014;29(1):8–10.CrossRef
33.
go back to reference Meyer P, Das T, Ghadiri N, Murthy R, Theodoropoulou S. Clinical pathophysiology of thyroid eye disease: the cone model. Eye. 2019;33(2):244–53.CrossRef Meyer P, Das T, Ghadiri N, Murthy R, Theodoropoulou S. Clinical pathophysiology of thyroid eye disease: the cone model. Eye. 2019;33(2):244–53.CrossRef
35.
go back to reference Nagy E, Toth J, Kaldi I, Damjanovich J, Mezosi E, Lenkey A, et al. Graves’ ophthalmopathy: eye muscle involvement in patients with diplopia. Eur J Endocrinol. 2000;1:591–7.CrossRef Nagy E, Toth J, Kaldi I, Damjanovich J, Mezosi E, Lenkey A, et al. Graves’ ophthalmopathy: eye muscle involvement in patients with diplopia. Eur J Endocrinol. 2000;1:591–7.CrossRef
Metadata
Title
Unusual onset of thyroid associated orbitopathy during pregnancy: case report and review of literature
Authors
Janos K. Aranyosi
Tamas Deli
Annamaria Erdei
Geza Toth
Attila Jakab
Mariann Fodor
Endre V. Nagy
Bernadett Ujhelyi
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2020
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-020-00663-9

Other articles of this Issue 1/2020

BMC Endocrine Disorders 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.